FTC Can't Block Theoretical Drugmaker Moves, Shire Says
The Federal Trade Commission is exceeding its authority by trying to preemptively block Shire ViroPharma Inc. from petitioning the U.S. Food and Drug Administration to delay generic competition based on theoretical...To view the full article, register now.
Already a subscriber? Click here to view full article